The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JANX | -47.18% | N/A | N/A | +9% |
| S&P | +12.57% | +87.93% | +13.44% | +59% |
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.00M | 2177.9% |
| Gross Profit | $9.50M | 13478.9% |
| Gross Margin | 94.99% | 111.2% |
| Market Cap | $1.47B | -38.0% |
| Market Cap / Employee | $14.26M | -58.5% |
| Employees | 103 | 49.3% |
| Net Income | -$24.31M | 13.4% |
| EBITDA | -$34.75M | 1.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $48.39M | 80.9% |
| Accounts Receivable | $7.50M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.38M | -6.3% |
| Short Term Debt | $2.28M | 35.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.85% | -0.7% |
| Return On Invested Capital | -29.35% | -21.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12.95M | -474.0% |
| Operating Free Cash Flow | -$12.86M | -476.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.27 | 1.56 | 1.35 | 1.46 | -59.39% |
| Price to Sales | 287.38 | 178.70 | 3257.28 | 151.59 | -20.30% |
| Price to Tangible Book Value | 4.27 | 1.56 | 1.35 | 1.46 | -59.39% |
| Enterprise Value to EBITDA | -71.58 | -19.69 | -10.23 | -15.81 | -69.75% |
| Return on Equity | -10.1% | -9.3% | -12.8% | -12.5% | 3.62% |
| Total Debt | $23.03M | $22.61M | $22.19M | $22.66M | -3.29% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
